SANA

Sana Biotechnology, Inc. (SANA) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Sana Biotechnology is a clinical-stage biotechnology company developing engineered cell therapies for Type 1 diabetes, oncology, and autoimmune diseases. The company operates as a single segment and is classified as an emerging growth company and a smaller reporting company. As of June 30, 2026, the company had 299.3 million shares of common stock outstanding.

Key Financial Metrics

Note: The company reported no revenue for the periods presented.

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by $30.2 million (32%) for the three months ended June 30, 2026, compared to the same period in 2025. This improvement was primarily driven by the absence of a $44.6 million non-cash impairment charge on long-lived assets recorded in Q2 2025.
• Increased Contingent Consideration Expense: Expenses related to the change in fair value of contingent consideration and success payments increased significantly to $23.9 million in Q2 2026 from $10.3 million in Q2 2025. This was due to changes in the estimated probability of achieving milestones and market capitalization assumptions.
• Operating Expense Reduction: Total operating expenses decreased by $29.6 million year-over-year for the quarter, largely due to the prior year's impairment charge and reduced personnel costs.
• Capital Raising: In Q2 2026, the company raised approximately $68.6 million in net proceeds through its At-The-Market (ATM) facility and $25.0 million from a stock purchase agreement with Mayo Clinic.

Guidance, Outlook, and Risks

• Going Concern Warning: Management has determined that current capital resources may not be sufficient to fund planned operations for at least one year from the date of the report. There is substantial doubt as to the company's ability to continue as a going concern without additional financing.
• Portfolio Prioritization: In November 2025, the company suspended development of two allogeneic CAR T programs (SC291 and SC262) to focus resources on SC451 (Type 1 diabetes) and SG293 (in vivo CAR T for B-cell malignancies/autoimmune diseases).
• Future Funding Needs: The company expects to incur additional losses and will require significant additional capital to advance clinical trials and commercialize products. It plans to address funding needs through equity or debt offerings and strategic collaborations.
• Legal Proceedings: A securities class action lawsuit filed in March 2025 regarding statements about the SC291 program remains pending. The court granted a stay of proceedings in May 2026.
• Success Payment Liabilities: The company has significant contingent liabilities related to the Cobalt acquisition (up to $500 million) and Harvard license (up to $175 million), which fluctuate based on stock price and market cap, impacting reported net loss.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $160.5 million liquidity position against the stated "substantial doubt" regarding the ability to fund operations for the next 12 months.
• Non-Cash Expenses: Analyze the impact of the $23.9 million increase in contingent consideration and success payment expenses on the reported net loss versus actual cash burn.
• Mayo Clinic Agreement: Confirm the status of the option for Mayo Clinic to purchase an additional 7.5 million shares (up to $25 million) by August 31, 2026.
• Program Status: Review progress on the IND filing and Phase 1/2 trial initiation for SC451 and SG293, which are now the sole focus of development.
• Legal Exposure: Monitor the status of the pending securities litigation and any potential settlement costs or reputational impact.